Imaging Biometrics Completes Phase I Trial of Gallium Maltolate for Recurrent Glioblastoma
Key Insights
Imaging Biometrics (search) successfully completed a phase I trial of oral gallium maltolate for recurrent or relapsed glioblastoma (search), meeting all predefined safety, tolerability, and pharmacokinetic objectives.
The trial demonstrated no significant adverse events, highlighting the favorable safety profile of gallium maltolate, a novel therapeutic targeting tumor metabolism (search) and iron-dependent cancer growth (search).
The company is now actively engaging with cancer centers to initiate phase II trials to further evaluate efficacy and expand clinical applications.
Imaging Biometrics (search) Ltd announced the successful completion of its phase I trial evaluating oral gallium maltolate (GaM) for the treatment of recurrent or relapsed glioblastoma (search), marking a significant milestone for the London-based healthcare imaging software firm. The trial met all predefined phase I objectives, including safety, tolerability, and pharmacokinetic benchmarks, positioning the company for advancement to phase II development.
Safety Profile Demonstrates Clinical Promise
The phase I trial demonstrated that significant adverse events were not observed, underscoring gallium maltolate's favorable safety profile. This safety data represents a crucial foundation for advancing the therapy in one of the most challenging oncological indications, where treatment options remain severely limited.
Oral gallium maltolate represents a novel therapeutic approach that targets tumor metabolism (search) and iron-dependent cancer growth (search) mechanisms. This mechanism-driven strategy offers a potentially differentiated approach to treating glioblastoma (search), a highly aggressive brain cancer with poor prognosis.
Clinical Development and Patient Response
"This achievement marks a pivotal step forward in our mission to bring novel, mechanism-driven therapies to patients with GBM," said Trevor Brown, Chief Executive Officer of Imaging Biometrics (search). The company highlighted encouraging data from the trial, including the continued treatment of one long-standing patient, which Brown noted "speaks to GaM's potential clinical benefit."
The completion of phase I development represents a critical regulatory milestone, providing the safety and tolerability data necessary to support expanded clinical testing. Brown indicated that the company looks forward to sharing the full summary analysis of the trial results in the near future.
Advancing to Phase II Development
With phase I objectives successfully achieved, Imaging Biometrics (search) is actively engaging with cancer centers to initiate a phase II trial. This next phase of development will focus on further evaluating gallium maltolate's efficacy while expanding the clinical footprint of the program.
The market responded positively to the clinical milestone, with shares of Imaging Biometrics (search) closing up 57% at 1.18 pence on Monday in London, reflecting investor confidence in the therapeutic potential of this novel approach to glioblastoma (search) treatment.